Effects of neoadjuvant chemotherapy on primary tumor and lymph node metastasis in esophageal squamous cell carcinoma: Additive association with prognosis

Diseases of the Esophagus

Volumn 22, Issue 4, 2009, Pages 291-297

  Akita, Hirofumi ^a   Doki, Yuichiro ^a,b   Yano, Masahiko ^a   Miyata, Hiroshi ^b   Miyashiro, Isao ^a   Ohigashi, Hiroaki ^a   Ishikawa, Osamu ^a   Nishiyama, Akiko ^b   Imaoka, Shingi ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Esophageal cancer; Lymph node metastasis; Neoadjuvant chemotherapy; Prognostic factor

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG EFFICACY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS SURGERY; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR VOLUME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOSCOPY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REFERENCE VALUES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 65949099129     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2008.00879.x     Document Type: Article

References (28)

1. Urschel J D, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003; 185: 538-43.
2. Group MRCOCW. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet 2002; 359: 1727-33.
3. Stahl M, Stuschke M, Lehmann N et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23: 2310-7.
4. Matsuyama J, Doki Y, Yasuda T et al. The effect of neoadjuvant chemotherapy on lymph node micrometastases in squamous cell carcinomas of the thoracic esophagus. Surgery 2007; 141: 570-80.
5. Kok T C, Van der Gaast A, Dees J et al. Cisplatin and etoposide in oesophageal cancer: A phase II study. Rotterdam Oesophageal Tumour Study Group. Br J Cancer 1996; 74: 980-4.
6. Kelsen D P, Ginsberg R, Pajak T F et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339: 1979-84.
7. Ilson D H, Forastiere A, Arquette M et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 2000; 6: 316-23.
8. Findlay M, Cunningham D, Norman A et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994; 5: 609-16.
9. Bamias A, Hill M E, Cunningham D et al. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: Response, toxicity, quality of life, and survival. Cancer 1996; 77: 1978-85.
10. Ando N, Iizuka T, Ide H et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: A Japan Clinical Oncology Group Study - JCOG9204. J Clin Oncol 2003; 21: 4592-6.
11. Yano M, Takachi K, Doki Y et al. Preoperative chemotherapy for clinically node-positive patients with squamous cell carcinoma of the esophagus. Dis Esophagus 2006; 19: 158-63.
12. Miyata H, Yano M, Doki Y et al. A prospective trial for avoiding cervical lymph node dissection for thoracic esophageal cancers, based on intra-operative genetic diagnosis of micrometastasis in recurrent laryngeal nerve chain nodes. J Surg Oncol 2006; 93: 477-84.
13. Yanagita S, Natsugoe S, Uenosono Y et al. Sentinel node micrometastases have high proliferative potential in gastric cancer. J Surg Res 2008; 145: 238-43.
14. Doki Y, Ishikawa O, Kabuto T et al. Possible indication for surgical treatment of squamous cell carcinomas of the esophagus that involve the stomach. Surgery 2003; 133: 479-85.
15. Doki Y, Ishikawa O, Takachi K et al. Association of the primary tumor location with the site of tumor recurrence after curative resection of thoracic esophageal carcinoma. World J Surg 2005; 29: 700-7.
16. International Union Against Cancer. TNM Classification of Malignant Tumours. New York: John Wiley and Sons, Inc., 2002.
17. Medich D, McGinty J, Parda D et al. Preoperative chemoradiotherapy and radical surgery for locally advanced distal rectal adenocarcinoma: pathologic findings and clinical implications. Dis Colon Rectum 2001; 44: 1123-8.
18. Kim D W, Kim D Y, Kim T H et al. Is T classification still correlated with lymph node status after preoperative chemoradiotherapy for rectal cancer? Cancer 2006; 106: 1694-700.
19. LaTulippe E, Satagopan J, Smith A et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 2002; 62: 4499-506.
20. Ramaswamy S, Ross K N, Lander E S, Golub T R. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003; 33: 49-54.
21. Yamasaki M, Takemasa I, Komori T et al. The gene expression profile represents the molecular nature of liver metastasis in colorectal cancer. Int J Oncol 2007; 30: 129-38.
22. Garrity M M, Burgart L J, Mahoney M R et al. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: A North Central Cancer Treatment Group Study. J Clin Oncol 2004; 22: 1572-82.
23. Farmer H, McCabe N, Lord C J et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-21.
24. Qubain S W, Natsugoe S, Matsumoto M et al. Micrometastases in the cervical lymph nodes in esophageal squamous cell carcinoma. Dis Esophagus 2001; 14: 143-8.
25. Adams S, Baum R P, Stuckensen T et al. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998; 25: 1255-60.
26. Nishimaki T, Tanaka O, Ando N et al. Evaluation of the accuracy of preoperative staging in thoracic esophageal cancer. Ann Thorac Surg 1999; 68: 2059-64.
27. Therasse P, Arbuck S G, Eisenhauer E A et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
28. Cunningham D, Allum W H, Stenning S P et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.